Difference between revisions of "Cabozantinib (Cometriq)"
Jump to navigation
Jump to search
m |
|||
| Line 22: | Line 22: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
===[[Hepatocellular carcinoma]]=== | ===[[Hepatocellular carcinoma]]=== | ||
| − | *1/14/2019: Approved for patients with [[Hepatocellular carcinoma|hepatocellular carcinoma (HCC)]] who have been previously treated with [[Sorafenib (Nexavar)|sorafenib]]. ''( | + | *1/14/2019: Approved for patients with [[Hepatocellular carcinoma|hepatocellular carcinoma (HCC)]] who have been previously treated with [[Sorafenib (Nexavar)|sorafenib]]. ''(New disease entity; based on CELESTIAL)'' |
===[[Thyroid_cancer#Medullary_thyroid_cancer | Medullary thyroid cancer]]=== | ===[[Thyroid_cancer#Medullary_thyroid_cancer | Medullary thyroid cancer]]=== | ||
| − | *11/29/2012: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm330213.htm Initial approval] (as Cometriq) for treatment of progressive metastatic [[Thyroid_cancer#Medullary_thyroid_cancer | medullary thyroid cancer (MTC)]]. | + | *11/29/2012: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm330213.htm Initial approval] (as Cometriq) for treatment of progressive metastatic [[Thyroid_cancer#Medullary_thyroid_cancer | medullary thyroid cancer (MTC)]]. ''(Based on EXAM)'' |
===[[Renal cell carcinoma]]=== | ===[[Renal cell carcinoma]]=== | ||
| − | *4/25/2016: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm497483.htm Approved] (as Cabometyx) for the treatment of advanced [[Renal_cell_carcinoma|renal cell carcinoma]] in patients who have received prior [[:Category:VEGFR_inhibitors|anti-angiogenic therapy]]. ''( | + | *4/25/2016: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm497483.htm Approved] (as Cabometyx) for the treatment of advanced [[Renal_cell_carcinoma|renal cell carcinoma]] in patients who have received prior [[:Category:VEGFR_inhibitors|anti-angiogenic therapy]]. ''(New disease entity; based on METEOR)'' |
| − | *12/19/2017: Granted FDA regular approval for treatment of patients with advanced [[Renal_cell_carcinoma|renal cell carcinoma (RCC)]]. ''( | + | *12/19/2017: Granted FDA regular approval for treatment of patients with advanced [[Renal_cell_carcinoma|renal cell carcinoma (RCC)]]. ''(Converted to regular approval; no longer requires prior treatment; based on CABOSUN)'' |
==Also known as== | ==Also known as== | ||
Revision as of 02:04, 25 May 2021
General information
Class/mechanism: Tyrosine kinase inhibitor; inhibits RET, MET/c-Met, VEGFR-1, VEGFR-2, VEGFR-3, KIT, TRKB, FLT-3, AXL, and TIE-2.[1][2][3][4][5][6]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1][4]
Diseases for which it is used
- Hepatocellular carcinoma
- Non-small cell lung cancer
- Prostate cancer
- Renal cell carcinoma
- Medullary thyroid cancer
Patient drug information
- Cabozantinib (Cometriq) package insert pages 20-24[1] (the numbering for the PDF is off, so in some PDF viewers, the patient information is on pages 27-31)
- Cabozantinib (Cabometyx) package insert[4]
- Cabozantinib (Cometriq) patient drug information (Chemocare)[7]
- Cabozantinib (Cometriq) patient drug information (UpToDate)[8]
History of changes in FDA indication
Hepatocellular carcinoma
- 1/14/2019: Approved for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. (New disease entity; based on CELESTIAL)
Medullary thyroid cancer
- 11/29/2012: Initial approval (as Cometriq) for treatment of progressive metastatic medullary thyroid cancer (MTC). (Based on EXAM)
Renal cell carcinoma
- 4/25/2016: Approved (as Cabometyx) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy. (New disease entity; based on METEOR)
- 12/19/2017: Granted FDA regular approval for treatment of patients with advanced renal cell carcinoma (RCC). (Converted to regular approval; no longer requires prior treatment; based on CABOSUN)
Also known as
Note: Cometriq is the brand name for cabozantinib's medullary thyroid cancer indication. Cabometyx is the brand name for cabozantinib's renal cell carcinoma indication.
- Code names: XL184, XL-184
- Brand names: Cabometyx, Caboxen, Cabozanib, Cabozanix, Cometriq, Lucicaboz
References
- ↑ 1.0 1.1 1.2 Cabozantinib (Cometriq) package insert
- ↑ Cabozantinib (Cometriq) package insert (locally hosted backup)
- ↑ Cometriq manufacturer's website
- ↑ 4.0 4.1 4.2 Cabozantinib (Cabometyx) package insert
- ↑ Cabozantinib (Cabometyx) package insert (locally hosted backup)
- ↑ Cabometyx manufacturer's website
- ↑ Cabozantinib (Cometriq) patient drug information (Chemocare)
- ↑ Cabozantinib (Cometriq) patient drug information (UpToDate)
Categories:
- Drugs
- Oral medications
- AXL inhibitors
- FLT3 inhibitors
- KIT inhibitors
- MET inhibitors
- RET inhibitors
- ROS1 inhibitors
- TEK inhibitors
- TRK inhibitors
- VEGFR inhibitors
- Hepatocellular carcinoma medications
- Non-small cell lung cancer medications
- Papillary renal cell carcinoma medications
- Prostate cancer medications
- Renal cell carcinoma medications
- Thyroid cancer medications
- FDA approved in 2012